Search results for "death"

showing 10 items of 1744 documents

Non-arbitrary minimum threshold of yearly performed pancreatoduodenectomies: National multicentric study

2021

Abstract Background Annual hospital volume of pancreatoduodenectomies could influence postoperative outcomes. The aim of this study is to establish with a non-arbitrary method the minimum threshold of yearly performed pancreatoduodenectomies in order to improve several postoperative quality outcomes. Method Prospective follow-up of patients submitted to pancreatoduodenectomy in participating hospitals during 1 year. The influence of hospital volume on quality outcomes was analyzed by univariable and multivariable models. The minimum threshold of yearly performed pancreatoduodenectomies to improve outcomes was established by Akaike’s information criteria. Results Data from 877 patients opera…

AdultMalemedicine.medical_specialtyPostoperative death030230 surgeryPancreaticoduodenectomyYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineHospital volumeRisk FactorsmedicineHumansAgedQuality of Health CareAged 80 and overbusiness.industryMargins of ExcisionLength of StayMiddle AgedHospitalsPancreatic NeoplasmsSpain030220 oncology & carcinogenesisMultivariate AnalysisEmergency medicineLymph Node ExcisionFemaleSurgerybusinessSurgery
researchProduct

Predictors of complicated grief in mourners of sudden cardiac death.

2021

AdultMalemedicine.medical_specialtyPsychological TraumaSudden cardiac deathLife Change EventsRisk FactorsmedicineHumansIntensive care medicineAgedPsychological Testsbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseObject AttachmentComplicated griefProlonged Grief DisorderCross-Sectional StudiesDeath Sudden CardiacEmergency MedicineFemaleGriefbusinessStress PsychologicalThe American journal of emergency medicine
researchProduct

Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design.

2014

Abstract Introduction and objectives Morbidity and mortality after admission for acute heart failure remain prohibitively high. In that setting, plasma levels of antigen carbohydrate 125 have shown to correlate with the severity of fluid overload and the risk of mortality and readmission. Preliminary data suggests a potential role of antigen carbohydrate 125 to guide therapy. The objective of this study is to evaluate the prognostic effect of an antigen carbohydrate 125-guided management strategy vs standard therapy in patients recently discharged for acute heart failure. Methods This is a multicenter, randomized, single-blind, efficacy trial study of patients recently discharged from acute…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsRisk AssessmentAntigenCause of DeathRisk of mortalityMedicineHumansIn patientSingle-Blind MethodProspective StudiesIntensive care medicineAgedHeart Failurebusiness.industryStandard treatmentDisease ManagementCardiovascular AgentsGeneral MedicineMiddle Agedmedicine.diseasePrognosisPatient DischargeClinical trialSurvival RateSpainHeart failureCA-125 AntigenAcute DiseaseFemalebusinessCarbohydrate antigenBiomarkersFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Analysis of thiamine transporter genes in sporadic beriberi

2014

Abstract Objective Thiamine or vitamin B 1 deficiency diminishes thiamine-dependent enzymatic activity, alters mitochondrial function, impairs oxidative metabolism, and causes selective neuronal death. We analyzed for the first time, the role of all known mutations within three specific thiamine carrier genes, SLC19 A2, SLC19 A3 , and SLC25 A19 , in a patient with atrophic beriberi, a multiorgan nutritional disease caused by thiamine deficiency. Methods A 44-year-old male alcoholic patient from Morocco developed massive bilateral leg edema, a subacute sensorimotor neuropathy, and incontinence. Despite normal vitamin B 1 serum levels, his clinical picture was rapidly reverted by high-dose in…

AdultMalemedicine.medical_specialtySLC19 A- SLC25 A19SLC19 AEndocrinology Diabetes and MetabolismGene mutationBeriberimedicine.disease_causeMitochondrial Membrane Transport Proteinslaw.inventionBeriberilawInternal medicineGenotypemedicineThiamine transporterObjective: Thiamine or vitamin B1 deficiency diminishes thiamine-dependent enzymatic activity alters mitochondrial function impairs oxidative metabolism and causes selective neuronal death. We analyzed for the first time the role of all known mutations within three specific thiamine carrier genes SLC19 A2 SLC19 A3 and SLC25 A19 in a patient with atrophic beriberi a multiorgan nutritional disease caused by thiamine deficiency. Methods: A 44-year-old male alcoholic patient from Morocco developed massive bilateral leg edema a subacute sensorimotor neuropathy and incontinence. Despite normal vitamin B1 serum levels his clinical picture was rapidly reverted by high-dose intramuscular thiamine treatment suggesting a possible genetic resistance. We used polymerase chain reaction followed by amplicon sequencing to study all the known thiamine-related gene mutations identified within the Human Gene Mutation Database. Results: Thirty-seven mutations were tested: 29 in SLC19 A2 6 in SLC19 A3 and 2 in SLC25 A19. Mutational analyses showed a wild-type genotype for all sequences investigated. Conclusion: This is the first genetic study in beriberi disease. We did not detect any known mutation in any of the three genes in a sporadic dry beriberi patient. We cannot exclude a role for other known or unknown mutations in the same genes or in other thiamine-associated genes in the occurrence of this nutritional neuropathy.HumansThiamineGenePolymerase chain reactionGeneticsMutationNutrition and DieteticsbiologyMembrane Transport ProteinsThiamine Deficiencymedicine.diseaseAlcoholismEndocrinologyMutationbiology.proteinThiamineMutations
researchProduct

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholeste…

2017

Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression.1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins. In a pivotal 78-week open-label trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia.2 The principal …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BSocio-culturaleFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologyMicrosomal triglyceride transfer proteinLDLTimeSudden cardiac deathHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineAdverse effectlomitapidebiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLlomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Carrier Proteins; Cholesterol LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Timemedicine.diseaseLomitapideCholesterolEndocrinologychemistrybiology.proteinBenzimidazolesFemalelipids (amino acids peptides and proteins)lomitapide; Cardiology and Cardiovascular Medicine; Physiology (medical)Carrier ProteinsCardiology and Cardiovascular MedicinebusinessLipoproteinCirculation
researchProduct

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

2021

Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monotherapy in first-line non-small-cell lung cancer. Here, we present the primary analysis data of cemiplimab in patients with locally advanced basal cell carcinoma after HHI therapy. Methods We did an open-label, multicentre, single-arm, phase 2 trial across 38 outpatient clinics, primarily at academic medical centres, in Canada, Europe, and the USA. Eligible patients (aged ≥18 years…

AdultMalemedicine.medical_specialtySkin NeoplasmsPyridinesProgrammed Cell Death 1 ReceptorVismodegibAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaClinical endpointOutpatient clinicHumansBasal cell carcinomaAnilidesHedgehog ProteinsLung cancerImmune Checkpoint InhibitorsAgedbusiness.industryStandard treatmentMiddle Agedmedicine.diseaseRegimenOncologyCarcinoma Basal CellDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drugThe Lancet. Oncology
researchProduct

Diabetes mellitus association with coronavirus disease 2019 ( COVID ‐19) severity and mortality: A pooled analysis

2020

Highlights There are ~ 2-fold increased odds of severe coronavirus disease 2019 (COVID-19) and a ~ 2-fold increased risk of odds of mortality in patients with history of diabetes mellitus compared to those without diabetes mellitus. Patients with a history of diabetes mellitus should be closely monitored if they get infected with COVID-19. Results of meta-analysis showing association of diabetes mellitus with severity (Panel A) of disease and mortality (Panel B) in coronavirus disease 2019 (COVID-19) patients.

AdultMalemedicine.medical_specialtyTime FactorsAdolescentendocrine system diseasesEndocrinology Diabetes and MetabolismPneumonia Viralcoronavirus030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologymedicine.disease_causeRisk AssessmentSeverity of Illness IndexCOVID-19 coronavirus diabetes mellitusBetacoronavirusYoung Adult03 medical and health sciences0302 clinical medicineCOVID‐19Risk FactorsCause of DeathInternal medicineDiabetes mellitusPandemicSeverity of illnessResearch LetterHumansMedicineYoung adultPandemicsAgedCoronavirusCause of deathAged 80 and overSARS-CoV-2business.industryCOVID-19Middle AgedPrognosismedicine.diseaseResearch LettersHost-Pathogen Interactionsdiabetes mellitusFemaleCoronavirus InfectionsbusinessRisk assessmentJournal of Diabetes
researchProduct

Therapeutic management in Sicilian patients with definite arrhythmogenic right ventricular dysplasia/cardiomyopathy and focus on the role of implanta…

2014

Arrhythmogenic Right Ventrticular Dysplasia/Cardiomyopathy(ARVD/C) is an inherited cardiomyopathy characterized by right ven-tricularmyocytelosswithfibrofattyreplacement,ahighriskofventric-ular arrhythmias (VA) and sudden cardiac death (SCD) [1]. Preventionof SCD represents the most important management strategy and theachievement of this target can be reached by different therapeuticstrategies including implantable cardioverter-defibrillator (ICD)implantation, pharmacologic therapy, catheter ablation of ventriculartachycardia (VT) and cardiac transplantation [2,3]. The aim of thisstudy is to examine the outcome of the different therapies adopted ina group of affected patients, focusing on th…

AdultMalemedicine.medical_specialtyTime FactorsCardiomyopathymedicine.medical_treatmentCardiomyopathyCatheter ablationImplantable cardioverterdefibrillatorSudden deathInternal medicinemedicineHumansMedical managementSicilySurvival rateArrhythmogenic Right Ventricular DysplasiaCardiomyopathy; Implantable cardioverterdefibrillator; Medical management; Predictors; Sudden deathSudden deathbusiness.industryPrognosisImplantable cardioverter-defibrillatormedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareDefibrillators ImplantableArrhythmogenic right ventricular dysplasiaSurvival RateTransplantationDeath Sudden CardiacTreatment OutcomeHeart failureCardiologyFemaleMorbidityCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesPredictorInternational Journal of Cardiology
researchProduct

Usefulness of concomitant myoglobin and troponin elevation as a biochemical marker of mortality in non–ST-segment elevation acute coronary syndromes

2003

Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 1996;334:1703–1708. 2. Senior R, Kaul S, Soman P, Lahiri A. Power-Doppler contrast echocardiography—a new technique for Assessing myocardial perfusion. Am Heart J 2000; 139:245–251. 3. Picano E, Parodi O, Lattanzi F, Sambuceti G, Andrade MJ, Marzullo P, Giorgetti A, Salvadori P, Marzilli M, Distante A. Assessment of anatomic and physiological severity of single-vessel coronary artery lesions by dipyridamole echocardiography. Comparison with positron emission tomography and quantitative arteriography. Circulation 1994;89:753–761. 4. Jayaweera AR, Wei K, Coggins M, Bin…

AdultMalemedicine.medical_specialtyTime FactorsCoronary DiseaseFractional flow reserveSensitivity and SpecificityHospitals UniversityCoronary artery diseaseElectrocardiographyRisk FactorsCause of DeathInternal medicineSpect imagingHumansMedicineFalse Positive ReactionsHospital MortalityAgedAged 80 and overAnalysis of VariancebiologyMyoglobinbusiness.industryMiddle AgedPrognosismedicine.diseaseTroponinTroponinDipyridamolemedicine.anatomical_structureCoronary stealSpainbiology.proteinCardiologyFemaleTriageCardiology and Cardiovascular MedicinebusinessPerfusionBiomarkersArterymedicine.drugThe American Journal of Cardiology
researchProduct

Prognostic Factors Determining Long-Term Survival in Well-Differentiated Thyroid Cancer: An Analysis of Four Hundred Eighty-Four Patients Undergoing …

2003

Identification of the prognostic factors relevant for long-term survival in differentiated thyroid cancer in a homogenously treated patient cohort in order to allow a better initial risk stratification.Four hundred eighty-four (358 females/126 males) patients with differentiated thyroid cancer (330 papillary [68.2%]; 154 follicular [31.8%]) were included. Inclusion criteria consisted of treatment with a uniform therapy scheme and continuous aftercare in the same institution. Initial diagnosis was between 1975-1995 (age at diagnosis, 14-84 years, median, 49.7). Tumor stage: pT1, n = 92; pT2, 211; pT3, 58; pT4, 123. Low-risk:or=pT3 NX M0, 331; high-risk pT4 and/or M1, 153. After thyroidectomy…

AdultMalemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndocrinologyRecurrenceCause of DeathInternal medicineAdenocarcinoma FollicularFollicular phaseLong term survivalmedicineHumansSurvivorsThyroid NeoplasmsThyroid cancerAgedNeoplasm StagingRetrospective StudiesCause of deathAged 80 and overbusiness.industryWell-Differentiated Thyroid CancerThyroidectomyRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryAdenocarcinoma PapillaryCohortFemalebusinessFollow-Up StudiesThyroid
researchProduct